公开(公告)号：US20230257479A1

公开(公告)日：2023-08-17

申请号：US17642488

申请日：2020-09-11

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C.W. BREIJ ,  Bart E.C.G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN ,  Reshma Abdulla RANGWALA ,  Sri GHATTA ,  Ruud BRAKENHOFF ,  Rieneke VAN DE VEN

IPC: C07K16/30 ,  A61P35/00 ,  A61P1/00

CPC classification number: C07K16/30 ,  A61P1/00 ,  A61P35/00 ,  A61K2039/505

Abstract: The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).

公开(公告)号：US20210230296A1

公开(公告)日：2021-07-29

申请号：US17228023

申请日：2021-04-12

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C. W. BREIJ ,  Bart E. C. G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20200277397A1

公开(公告)日：2020-09-03

申请号：US16813167

申请日：2020-03-09

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C. W. BREIJ ,  Bart E. C. G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN

IPC: C07K16/30 ,  C12N15/79 ,  A61P35/00

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20240228641A9

公开(公告)日：2024-07-11

申请号：US18478711

申请日：2023-09-29

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Patrick ENGELBERTS ,  Kristel KEMPER ,  Esther C. W. BREIJ ,  Simone OOSTINDIE ,  Farshid ALEMDEHY

IPC: C07K16/28 ,  A61P35/00 ,  C12N15/63

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2809 ,  C12N15/63 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/565

Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.

公开(公告)号：US20240132607A1

公开(公告)日：2024-04-25

申请号：US18478711

申请日：2023-09-28

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Patrick ENGELBERTS ,  Kristel KEMPER ,  Esther C. W. BREIJ ,  Simone OOSTINDIE ,  Farshid ALEMDEHY

IPC: C07K16/28 ,  A61P35/00 ,  C12N15/63

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2809 ,  C12N15/63 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/565

Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.

公开(公告)号：US20230310599A1

公开(公告)日：2023-10-05

申请号：US18023808

申请日：2021-09-02

Applicant: GENMAB A/S

Inventor： Hreinn BENONISSON ,  Jim MIDDELBURG ,  Thorbald VAN HALL ,  Isil ALTINTAS ,  Kristel KEMPER ,  Janine SCHUURMAN ,  Katy Ann LLOYD ,  Vitalijs OVCINNIKOVS ,  Gijsbertus ZOM

IPC: A61K39/42 ,  A61P35/00 ,  A61P37/04

CPC classification number: A61K39/42 ,  A61P35/00 ,  A61P37/04 ,  A61K2039/545

Abstract: The present invention relates to combination therapy within the field of oncology; in particular to combination therapy with vaccines and binding agents binding to CD3 and to a target antigen on tumor cells.

公开(公告)号：US20210070877A1

公开(公告)日：2021-03-11

申请号：US17077376

申请日：2020-10-22

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C. W. BREIJ ,  Bart E. C. G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.